Dr Lal PathLabs Limited, one of India’s leading diagnostic and healthcare service providers, reported a strong financial performance for the first quarter of FY27, with consolidated revenue rising 19.1% year-on-year to Rs. 798 crore.

 

The company announced its financial results for the quarter ended June 30, 2026, highlighting robust growth across key performance metrics, improved profitability, and strategic expansion initiatives.

 

Lal PathLabs reported a significant improvement in operational performance, with EBITDA climbing 28.7% to Rs. 247 crore in Q1 FY27, compared with Rs. 192 crore in the corresponding period last year. The EBITDA margin expanded to 31.0% from 28.7%.

 

Profit after tax (PAT) increased 27.2% to Rs. 170 crore, compared with Rs. 134 crore in Q1 FY26, with the PAT margin improving to 21.4% from 20.0%.

 

The company’s earnings per share (EPS) stood at Rs. 10.1, registering a growth of 27.8% over Rs. 7.9 in the same period last year.

 

The company maintained a strong balance sheet, with cash and cash equivalents standing at Rs. 1,693 crore as of June 30, 2026.

 

The Board also announced an interim dividend of 50%, amounting to Rs. 5 per share.

 

As part of its growth strategy, Dr Lal PathLabs acquired an 80% equity stake in Sunshine Healthcare Limited, Ghana, a company engaged in the diagnostic business. The transaction consideration will not exceed GHS 45.6 million.

 

The company also acquired a 30% equity stake in Neuome Technologies Private Limited, which focuses on innovative solutions in sample preservation and biobanking, for a consideration not exceeding Rs. 3.5 crore.